[1] |
LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong.
Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
|
[2] |
ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge.
Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
|
[3] |
LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng.
Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753.
|
[4] |
MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan.
Oral lienal peptides improve ammonia-induced coughing and inflammation in mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607.
|
[5] |
JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan.
Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
|
[6] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
[7] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
[8] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|
[9] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[10] |
WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian.
Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
|
[11] |
YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili.
Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
|
[12] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[13] |
CHEN Yu, GU Bing, LI Huanan.
Modulating gut miocrobiota: a new strategy in the treatment of gout
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
|
[14] |
CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong.
Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
|
[15] |
LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei.
Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.
|